Multi-Center PAMPA Study

Exclusion Criteria

• •1. Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;
• •2. Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);
• •3. RA seropositivity (mid-high RF/ACPA titers);
• •4. Current active malignancy;
• •5. History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development
• •6. Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;
• •7. Known hypersensitivity to the study agent.